Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 5/20 | 0.41 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD5 | P21918 | 2/20 | 0.41 |
| ▸ | HHAT | Q5VTY9 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4751918 | 0.81 | DRD2 (0.42) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL2836553 | 0.79 | GRIN2B (0.41) | DRD2DRD3HHATKMT2AGRIN2B | |
| SCHEMBL4751245 | 0.77 | DRD2 (0.40) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL3304815 | 0.77 | DRD2 (0.40) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL3307496 | 0.76 | HHAT (0.45) | DRD1HHATKMT2AGRIN2BMAPK1 | |
| SCHEMBL3307502 | 0.76 | HHAT (0.45) | DRD1HHATKMT2AGRIN2BMAPK1 | |
| SCHEMBL4751946 | 0.76 | HHAT (0.45) | DRD1HHATKMT2AGRIN2BMAPK1 | |
| SCHEMBL26608671 | 0.74 | SIGMAR1 (0.56) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL2839500 | 0.72 | NPC1 (0.46) | DRD1DRD2DRD3DRD4DRD5 | |
| SCHEMBL2994358 | 0.72 | SMN1; SMN2 (0.42) | HHAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217031-B2 | Heteroaryl derivatives | NIPPON SHINYAKU CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100048537-A1 | HETEROARYL DERIVATIVES | NIPPON SHINYAKU CO., LTD. (JP) | 2010-02-25 | — | — | US | disclosed |
| EP-2141168-A1 | HETEROARYL DERIVATIVES | Nippon Shinyaku Co., Ltd. (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048537-A1 | HETEROARYL DERIVATIVES | OPRD1, OPRM1, OPRK1 | DRD1 40/4885DRD2 58/4885DRD3 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.